AD-17002 is under clinical development by Advagene Biopharma and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AD-17002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AD-17002 overview

AD-17002 is under development for the treatment of house dust mite (HDM) allergic rhinitis, eosinophilic asthma and Coronavirus Disease 2019 (Covid-19). The therapy consist of Lth(alpha K) an enterotoxin adjuvant combined HDM allergen. It is administered through intra nasal route and developed based on detoxified LT adjuvant technology platform.

Advagene Biopharma overview

Advagene Biopharma is a Taiwan-based company mainly enagegd in the research and development of new drug products through its detoxified LT adjuvant technology platform. The products developed by the Company include nasal spray influenza vaccine (LT

For a complete picture of AD-17002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.